Dispatch Bio is developing the Flare platform, which uses a viral vector to deliver a novel, universal antigen (Flare) to target tumor cells and neutralize the immune-suppressive tumor environment. The platform is engineered to enable the immune system to identify and eliminate solid tumor cells while sparing healthy tissue. The company announced a total of $216 million in funding, including a recently closed Series A. Dispatch was founded in 2022 out of a collaboration with the Parker Institute for Cancer Immunotherapy (PICI) and leverages technologies from the labs of Andy Minn, Carl June, Chris Garcia, and Kole Roybal. Leadership includes CEO Sabah Oney and a board and scientific advisory team composed of academic and industry figures. The funding will be used primarily to advance Dispatch’s therapeutic candidates into first-in-human clinical studies, with the first program expected to enter the clinic in 2026.

Total raised

$216M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2025